Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
Metrics: PDF 969 views | Full Text 1830 views | ?
Hideyuki Matsushima1, Masaki Kaibori1, Masahiko Hatta1, Morihiko Ishizaki1, Richi Nakatake1, Tadayoshi Okumura1,2, Kengo Yoshii3 and Tomoki Todo4
1 Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan
2 Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga, Japan
3 Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan
4 Division of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
|Masaki Kaibori,||email:||[email protected]|
Keywords: oncolytic virus; herpes simplex virus; neuroendocrine tumor; mouse xenograft model
Received: August 22, 2019 Accepted: December 02, 2019 Published: December 24, 2019
BACKGROUND: Few chemotherapies are available for neuroendocrine tumors, especially for highly malignant neuroendocrine cancers. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 selectively replicates in tumor cells and shows cytotoxicity against tumor cells without damaging surrounding normal tissues. We examined the antitumor effect of T-01 to explore novel treatments for patients with neuroendocrine tumors.
METHODS: The cytotoxicity of T-01 was tested in two human and one murine neuroendocrine tumor cell lines in vitro. Mouse models with subcutaneously implanted human neuroendocrine tumor QGP1 cells were used to investigate T-01 efficacy in vivo.
RESULTS: T-01 showed cytotoxicity against the three cell lines in vitro. In xenograft models, the growth of tumors derived from QGP1 cells was inhibited by T-01 compared with control group. Although weight loss of mice was observed with tumor growth in the control group, it was suppressed by T-01 administration. The antitumor effects of T-01 were dependent on virus concentration and frequency of administration.
CONCLUSIONS: T-01 effectively inhibits tumor cell proliferation in a poorly differentiated NEC mouse model. These results suggest that the third-generation oncolytic HSV-1 may serve as a novel treatment for patients with neuroendocrine tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.